Introducing the new Oxlife LIBERTY 2® POC

O2 Concepts® introduces the new Oxlife LIBERTY 2® POC, now delivering 2.0 LPM continuous flow in a wearable device

Middlebury, Connecticut, January 2, 2024 — O2 Concepts® announced an expansion of the continuous flow capabilities of their most advanced POC technology, the Oxlife LIBERTY®.

Building on the existing Oxlife LIBERTY® offering, the innovative new Oxlife LIBERTY 2® brings even more choice to DME customers and patients with an increased continuous flow capability (up to 2.0 LPM) and the industry’s largest pulse flow settings available (1-10) in a compact, wearable design. Providing patients, clinicians and DMEs with a reliable and durable single device solution across a large spectrum of therapeutic needs.

“With Oxlife LIBERTY 2®, clinicians and DMEs no longer have to choose between the robust continuous flow therapy of a stationary device and the mobility of a wearable POC,” commented Elby Beal, Managing Partner and CEO of O2 Concepts®. “Oxlife LIBERTY 2® offers the unique combination of therapy efficacy and operating efficiency and has the ability to change what it means to provide, prescribe and live with oxygen therapy.”

The Oxlife LIBERTY® also features the company’s market leading proprietary DNA Technology® (Dynamic Network Analysis) — an intelligent, device-initiated cellular technology — that connects DMEs with device data for new levels of operating efficiency, asset management and inventory control and provides clinicians with critical telemedicine data for improved patient outcomes.

Oxlife LIBERTY 2® is available for shipping now.

For more information on Oxlife LIBERTY® and Oxlife LIBERTY 2® by O2 Concepts®, visit our products page.